Doheny Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Doheny Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,375	Closed	-$325K	–	105
2020 Q4	$325K	Buy	+1,375	New	+$315K	0.23%	82
2019 Q2	–	Sell	-2,300	Closed	-$423K	–	98
2019 Q1	$423K	Sell	2,300 -1,800	-44%	-$332K	0.36%	70
2018 Q4	$679K	Buy	4,100 +125	+3%	+$21.7K	0.5%	50
2018 Q3	$766K	Buy	3,975 +575	+17%	+$102K	0.4%	60
2018 Q2	$578K	Buy	+3,400	New	+$527K	0.31%	69
2016 Q2	–	Sell	-9,400	Closed	-$747K	–	107
2016 Q1	$747K	Hold	9,400	–	–	0.39%	59
2015 Q4	$1.18M	Sell	9,400 -2,510	-21%	-$303K	0.58%	50
2015 Q3	$1.24M	Sell	11,910 -10	-0.1%	-$1.28K	0.64%	47
2015 Q2	$1.47M	Buy	11,920 +375	+3%	+$47.3K	0.66%	49
2015 Q1	$1.36M	Buy	+11,545	New	+$1.38M	0.63%	47

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Doheny Asset Management's VRTX Position: Q1 2021 in Review

Doheny Asset Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2021, closing a stake of 1,375 shares — an estimated $325K sold.

Doheny Asset Management first reported a position in VRTX in Q1 2015 and held it in 10 quarters. The position peaked at $1.47M in Q2 2015. 1,000 funds tracked by Wall St. Rank hold VRTX as of Q1 2021.

Doheny Asset Management reported no remaining Vertex Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Doheny Asset Management sold 1,375 Vertex Pharmaceuticals shares in Q1 2021, an estimated $325K.
Doheny Asset Management first reported a position in Vertex Pharmaceuticals in Q1 2015 and held it in 10 quarters.
Doheny Asset Management's Vertex Pharmaceuticals position peaked at $1.47M in Q2 2015.
1,000 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2021.

Based on Doheny Asset Management's 13F filing for Q1 2021, filed 17 May 2021.